EPA:DASA 14 January 2026

March 20, 2026, 7:08 PM EDT. Novavax (NVAX) shares closed at $9.62, down 1.23%, outperforming the broader market declines as the S&P 500 fell 1.51%. Over the past month, Novavax gained 5.58%, surpassing the Medical sector's 7.54% loss. Investors await the company's financial results, expecting a substantial earnings per share (EPS) decline of 110.58% year-over-year to -$0.31 and revenues forecasted to fall 91.63% to $55.78 million. Full-year estimates also show significant drops. Despite this, the Zacks Consensus EPS estimate recently rose 47.68%, leading to a Zacks Rank of #3 (Hold) for Novavax. The Medical - Biomedical and Genetics industry ranks in the bottom 42% of all industries, reflecting sector challenges. Market watchers are advised to monitor updates closely as Novavax navigates these headwinds.